studied clinically are detailed in this review, because the clinical importance of theoretical interactions cannot be properly assessed. The drug-drug interactions were tabulated according to risk category, with the most relevant category mentioned first. Within each category, the interacting agent is the primary determinant. Advice on how to cope with specific interactions has been provided as clearly as possible.
There are currently a number of licensed azole antifungal drugs; however; only 4 (namely, fluconazole, itraconazole, posaconazole, and voriconazole) are used frequently in a clinical setting for prophylaxis or treatment of systemic fungal infections. In this article, we review the pharmacokinetic interactions of these azole antifungal drugs with other coadministered agents. We describe these (2-way) interactions and the extent to which metabolic pathways and/or other supposed mechanisms are involved in these interactions. This article provides an overview of all published drug-drug interactions in humans (either healthy volunteers or patients), and on the basis of these findings, we have developed recommendations for managing the specific interactions.
Azole antifungal drugs exhibit a wide range and variety of drugdrug interactions. They are a substrate for and inhibitors of cytochrome P450 (CYP450) enzymes, as well as inhibitors of membrane transporters such as P-glycoprotein (P-gP). The inhibition or induction of CYP450 enzymes may alter the pharmacokinetic profile of the drugs involved and can thus affect both interacting agents. This type of interaction should be avoided whenever possible, because it can lead to either overdosing or underdosing of both drugs, leading to toxicity or to loss of efficacy, respectively. The risk of this type of pharmacokinetic interaction occurring between an azole antifungal drug and other drug classes can differ, depending on the individual drugs involved, even for drugs within the same class.
METHODS
A PubMed search of peer-reviewed journals and review articles was performed using the keywords "antifungal," "pharmacokinetics," "metabolism," "drug interactions," and the names of the individual antifungal drugs. Only drug-drug interactions the drug being metabolized [7, 8] . The elimination half-life for adults is ∼30 h but is markedly reduced in children (15-25 h) [3] . For patients with renal failure, the maintenance dose has to be reduced by 50% [3] . For patients requiring hemodialysis, 1 full dose (100%) should be administered after every dialysis session [3] .
Itraconazole. The oral formulation of itraconazole consists of capsules and an oral solution. Capsules have a less favorable pharmacokinetic profile, compared with the oral solution [9] . Systemic bioavailability of itraconazole oral solution is ∼55% and is optimized under fasting conditions [10, 11] . Itraconazole is highly protein bound (199%) [12] and penetrates extensively into human tissue [13] , but it has limited penetration into the cerebrospinal fluid [14] . Itraconazole is extensively metabolized by the liver, predominantly by the CYP3A4 isoenzyme system, and is known to undergo enterohepatic recirculation [15] . Hydroxy-itraconazole is the major metabolite and shows an antifungal activity equal to that of the parent compound. Metabolites of itraconazole are excreted into the urine (40% of metabolites) and bile (55% of metabolites). Itraconazole is a substrate for and an inhibitor of CYP3A4 and an inhibitor of P-gP [10, 16] .
Voriconazole. Voriconazole, given orally, is rapidly and almost fully absorbed (oral bioavailability 190%), with a maximum plasma concentration (C max ) being achieved ∼2 h after administration under fasting conditions [17] . The volume of distribution of voriconazole is estimated to be ∼4.6 L/kg, with a plasma protein binding of ∼58% [18] . Voriconazole is extensively distributed into tissues and penetrates well into cerebrospinal fluid [19, 20] and into vitreous and aqueous humors [21] [22] [23] . The steady state plasma concentrations of voriconazole in healthy volunteers are reached after 5-7 days of treatment but can be reached after 24 h by giving a loading dose [24] [25] [26] . Voriconazole exhibits nonlinear pharmacokinetics, with a C max and an area under the concentration-time curve (AUC) that increase more than proportionally with an increase in dose, possibly because of saturation of the hepatic metabolism of the drug. The major redundant metabolic pathway involves CYP2C19, with CYP2C9 and CYP3A4 being involved to a much lesser extent. The major metabolite of voriconazole possesses no antifungal activity. Voriconazole is an inhibitor of CYP2C9, CYP2C19, and CYP3A4. The drug's metabolites are primarily excreted in the urine [18] . The apparent serum half-life of voriconazole is ∼6 h, but it can become longer with a higher dosage [27] .
Posaconazole. Posaconazole is only available as an oral formulation. Like itraconazole, posaconazole is absorbed slowly, with a time to median maximum absorption of 5 h, and is also strongly bound to plasma proteins (198%). The volume of distribution varies considerably, and steady state is reached after a period of 7-10 days [28] [29] [30] [31] . Administration of 50-800 mg to healthy volunteers resulted in a linear pharmacokinetic profile [29] , and doses of 1800 mg showed no marked increase in total exposure. Administration of posaconazole in 2 or 4 divided daily doses leads to a 2-fold or 3-fold increase in exposure, respectively, compared with administration of 1 daily dose. Posaconazole is metabolized by a phase II reaction (uridine diphosphate-glucuronosyltransferase 1A4 enzyme system) and converted into a nonactive metabolite [32, 33] . Approximately 78% of the drug is recovered in fecal samples [33] , and most of the metabolites are excreted into the urine with an elimination half-life of the parent compound of ∼35 h (range, 20-66 h) [29] . Posaconazole is a substrate for P-gP in vitro.
MECHANISMS OF DRUG-DRUG INTERACTION
In general, pharmacokinetic interactions occur at the level of drug absorption, distribution, excretion, and metabolism, with the frequent involvement of the CYP450 metabolizing enzyme system and drug transporters such as P-gP (figure 1). The results of these interactions can be a decrease or an increase in exposure to both interacting drugs, which can in turn lead to reduced efficacy or increased toxicity, respectively. The mechanisms involved in pharmacokinetic drug-drug interactions are outlined in the following sections.
PHARMACOKINETIC INTERACTIONS

Drug Absorption
All 4 antifungal drugs (i.e., fluconazole, itraconazole, posaconazole, and voriconazole) discussed in this review can be given orally and require absorption through the mucous membranes of the gastrointestinal tract; therefore, a change in plasma concentrations can be the result of incomplete drug absorption. Drug absorption and, thus, the pharmacokinetic profile of a drug can be substantially influenced by gastric pH or by the presence of food.
Effect of food on the absorption of azoles. The pharmacokinetics and bioavailability of fluconazole are not affected by food. The mean bioavailability of itraconazole oral solution under steady state conditions was 43% higher for those who fasted than for those who did not [34] . Single and multiple oral doses of voriconazole with food lowered the bioavailability by ∼22% and delayed absorption, compared with single and multiple oral doses of voriconazole without food [35] . Administration of voriconazole with a high-fat meal reduced the mean C max and AUC by 34% and 24%, respectively [18] . For this reason, oral administration is recommended either 1 h before or 1 h after meals. Posaconazole absorption is strongly affected by the presence and composition of food. The mean AUC and C max values increased by ∼400% when posaconazole was administered with a high-fat meal, compared with when it was administered under fasting conditions [36] . The administration of posaconazole with a nonfat meal enhanced expo- sure, resulting in a 2.6-fold increase in the AUC and a 3.0-fold increase in the C max , relative to the administration of posaconazole under fasting conditions [37, 38] . The coadministration of posaconazole with a nutritional supplement resulted in a 3.4-fold increase in the C max and a 6-fold increase in the AUC, relative to the administration of posaconazole under fasting conditions [39] . The daily dose of posaconazole should be divided for malnourished patients (e.g., 200 mg 4 times a day).
Effect of gastric pH and acid-reducing agents on the absorption of azoles.
The absorption of fluconazole is not affected by drugs that increase gastric pH [40] . The concomitant administration of itraconazole and proton pump inhibitors (e.g., omeprazole) or H 2 receptor antagonists (e.g., famotidine and ranitidine) leads to impaired absorption of itraconazole, resulting in a decrease in exposure [10] .
The absorption of voriconazole is not markedly influenced by antacids or proton pump inhibitors, although the mean C max and AUC values of voriconazole are increased by 15% and 41% when coadministered with omeprazole, because of the inhibition of plasma clearance of voriconazole [41] . The C max and AUC values of posaconazole were both reduced by 39% when coadministered with cimetidine (400 mg twice daily), possibly as a result of decreased gastric acid production. The effects of proton pump inhibitors (e.g., esomeprazole) that may suppress gastric acidity for several hours have only been presented in abstract form [36] . The concomitant administration of posaconazole with esomeprazole resulted in a 33% decrease in posaconazole exposure [28] .
Not only the gastric pH but also the integrity of the gastrointestinal tract may be important factors for the absorption of antifungal drugs. For instance, posaconazole absorption appeared to be reduced in patients with grade 1 or grade 2 mucositis, compared with patients without mucositis (AUC for 400 mg of posaconazole twice daily, 4.54 vs. 8.85 mg ϫ h/L) [42] .
Metabolism
Drug metabolism mainly occurs in the liver, where 2 types of reactions occur. Most drugs are metabolized by phase I reactions that involve oxidation, reduction, and hydrolysis principally involving the CYP450 enzymes. In contrast, phase II reactions are not mediated by CYP enzymes but involve the conjugation of the drugs. Drugs can be substrates, inducers, or inhibitors. Substrates are moieties that undergo metabolism by у1 enzyme. Enzyme induction can lead to either increased drug exposure (in the case of a prodrug) and decreased drug exposure, with subsequent decreased effect. It may take from up to a few days to 2-3 weeks for enzyme induction to reach its full extent. Enzyme inhibition, on the other hand, is instantaneous and is dependent on the dose of the drug.
Effect of Azole Antifungal Drugs on Comedication
All azoles inhibit the CYP3A4 isoenzyme (figure 1). In humans, CYP3A comprises the largest fraction of the total CYP content and is responsible for the metabolism of a broad range of drugs. Furthermore, CYP3A4 is involved in presystemic metabolism in the gastrointestinal tract, influencing the absorption of CYP3A substrates. The inhibitory potential of each of the azole antifungal drugs varies greatly: itraconazole and posaconazole are more-potent inhibitors of CYP3A4 than are fluconazole or voriconazole. In addition to CYP3A4, fluconazole and voriconazole are also strong noncompetitive or mixed-type inhibitors of CYP2C9 and CYP2C19 [27, 43, 44] . The clinical relevance of the pharmacokinetic interactions depends on the CYP isoform that metabolizes the coadministered drug and on the potency of the antifungal agent as an inhibitor of that isoform. 
NOTE.
All of the patients who participated in a study protocol were included in the number of participants. In the case of a controlled study, the control group was included in the total amount of participants. In the case of 2 research arms, both arms were included. "Antifungal agent" describes which antifungal agent is involved in the drug-drug interaction. More than 1 antifungal agent can be presented for a coadministered agent; this occurs when information on a drug interaction with an antifungal agent is presented with supposed different effects. In the case of multiple drugs being investigated, only the number of the patients who experienced in an azole interaction (including control group) is mentioned. The most plausible interaction mechanism is given. Some drug-drug interactions are based on theoretical considerations (e.g., because it is known that the drugs are metabolized by the same cytochrome protein [CYP] isoenzymes). Recommendations might reflect the opinions of the authors of the published articles but may also differ slightly, on the basis of interpretation from multiple studies and gathered information. Therapeutic drug monitoring (TDM) of selected azole antifungals is currently considered as an additional clinical tool, because relationships have been described between plasma concentrations and efficacy and/or toxicity [203] [204] [205] [206] . A validated assay needs to be used to determine adequate plasma concentrations, and the interpretation of the results should be performed by a qualified person (e.g., clinical pharmacist and/or clinical pharmacologist). If a drug-drug interaction was not supported by a study, then it was based on another drug interaction with a coadministered agent that is structurally similar. In addition, the drug-drug interaction can be based on knowledge of the metabolic pathway of the drugs involved and/or the drugs' capacity to inhibit or induce this metabolic pathway. AUC, area under the concentration-time curve; BMT, bone marrow transplantation; CF, cystic fibrosis; CGD, chronic granulomatous disease; C max , maximum plasma concentration; C min , minimum plasma concentration; CsA, cyclosporine A; C ss , concentration in steady state; ESRD, end-stage renal disease; a Data demonstrate that the specified agents may interact with each other in a clinically significant manner. The risks associated with concomitant use of these agents usually outweigh the benefits. These agents are generally considered to be contraindicated. b Data demonstrate that the 2 medications may interact with each other in a clinically significant manner. A patient-specific assessment must be conducted to determine whether the benefits of concomitant therapy outweigh the risks. Specific actions must be taken to realize the benefits and/or minimize the toxicity resulting from concomitant use of the agents. These actions may include aggressive monitoring, empirical dosage adjustments, and/or choosing alternative agents.
c Data demonstrate that the specified agents may interact with each other in a clinically significant manner. The benefits of concomitant use of these 2 medications usually outweigh the risks. An appropriate monitoring plan should be implemented to identify potential negative effects. Dosage adjustments of 1 or both agents may be needed in a minority of patients.
d Data demonstrate that the specified agents may interact with each other, but there is little to no evidence of clinical concern resulting from their concomitant use. e Data have not demonstrated either pharmacodynamic or pharmacokinetic interactions between the specified agents.
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Effect of Comedication on Azole Antifungal Drugs
Itraconazole and voriconazole are metabolized by the liver via phase I reactions. Voriconazole is a substrate for CYP2C19 and, to a lesser extent, for CYP2C9 and CYP3A4 [45, 46] . Itraconazole is predominantly metabolized by CYP3A4 and is the only azole antifungal drug with an active metabolite [13, 15] . Fluconazole is mainly excreted unchanged into the urine, and hepatic metabolism via CYP3A4 accounts for only 11% of the total drug excreted [6] . It is therefore unlikely that the interactions that influence the pharmacokinetic profile of fluconazole originated from this enzyme system. Posaconazole metabolism involves phase II reactions (i.e., glucuronidation of the drug) [32] . The drugs that influence phase II enzyme systems, such as lopinavir plus ritonavir [47] , can exert a change in the pharmacokinetic profile of the azole drug involved, leading to increased or decreased exposure.
Genetic Polymorphism of CYP450 Enzyme Systems
All enzymes involved in the metabolism of azole antifungal drugs are known to have multiple polymorphisms that divide the population into poor metabolizers and extensive metabolizers. Patients who are homozygous or heterozygous poor metabolizers have a limited enzymatic capacity for the isoenzyme, which leads to a lower metabolic turnover of the drug involved and, thus, higher exposure. Polymorphisms of CYP2C9 and CYP2C19 may play a clinically relevant role, whereas polymorphisms of CYP3A4 are not considered clinically relevant.
In homozygous poor metabolizers of CYP2C19, the C max and AUC values of voriconazole are 2-5 times higher than those values in extensive metabolizers [48] . The CYP2C9 genotypic variation does not significantly influence the exposure to voriconazole, because only a small fraction of the drug is metabolized through this enzymatic pathway [49] . The prevalence of variations in the gene sequence differs by race, with 20%-30% of Asian persons and 2%-3% of white persons being homozygous poor metabolizers of CYP2C19 [50] . Determining the CYP2C19 genotype before initiation of therapy may predict possible toxicity; Asian patients might especially benefit from this approach. A cost-benefit analysis should be performed before using this approach in general practice. We do not recommend determining genotype before initiation of therapy, because the monitoring of plasma concentrations and clinical signs provide a better basis for management.
Drug Transporters
Active transporters, such as P-gP, organic anion-transporting polypeptides (OATPs), and breast cancer resistant protein (BCRP), play an important role in drug-drug interactions by regulating the access of drugs to the drug-metabolizing enzymes and by controlling drug concentrations in enterocytes and hepatocytes. Thus, the contribution of efflux transporters in drug-drug interactions cannot be excluded [16, 51] ; however, there is a lack of convincing data on the clinical relevance of drug transporters. P-gP. P-gP acts as an energy-dependent efflux pump that exports substrates out of the cell and is an important molecular determinant of oral bioavailability, brain penetration, and treatment resistance to several therapeutically used drugs. The modulation of the P-gP function may play a significant role in drugdrug interactions. Two azole antifungal drugs-itraconazole and posaconazole-are substrates for and inhibitors of P-gP of the multidrug resistance-1 gene [16, 28] . In vivo, no concrete relationship between azole antifungal drugs and P-gP has been established [51] .
Other transporter systems. The OATP 1B1 is a multispecific carrier capable of bidirectional transportation across the sinusoidal liver membrane [52] . For instance, atorvastatin is subject to cellular membrane transport by OATP 1B1 and P-gP. It is suggested that itraconazole might block the transportation of atorvastatin because of the inhibition of the OATP 1B1 enzyme system [53] . The exact role of OATP, however, has not been established, and thus, its specific role in drug-drug interactions with selected substrates and inhibitors, such as itraconazole, remains unclear and requires further investigation.
The human BRCP belongs to the OATP-binding cassette transporter family. The BCRP does not seem to be inhibited by fluconazole or voriconazole. A simulation model has demonstrated that it is highly likely that the BCRP is inhibited by itraconazole [54] . In vivo, no relationship between azole antifungal drugs and the BCRP has been established.
RENAL EXCRETION
Drug interactions based on alterations in renal elimination mainly involve changes in tubular secretion or changes in kidney function. Drugs that use the same active transportation system in the kidney tubules can compete for this excretory system. The 2 drugs excreted by the kidneys are fluconazole and hydroxy-itraconazole. There have been no reports to date that have shown that impaired renal function caused by nephrotoxic drugs such as cyclosporine or gentamicin has led to increased toxicity of fluconazole or hydroxyl-itraconazole as a result of increased exposure.
PREDICTION OF DRUG-DRUG INTERACTIONS
Drug-drug interactions can cause many clinical problems. Ideally, comprehensive information should be available before a new drug completes the registration process. Because we aim for the maximum attainable therapeutic effect when treating invasive fungal disease, it is important to be aware of the mechanisms, whether theoretical or proven, behind drug-drug interactions. Currently, software tools are available that can fa-at Katholieke Universiteit on November 1, 2012 http://cid.oxfordjournals.org/ Downloaded from cilitate rapid monitoring for interactions, thereby assisting in the clinical decision-making process.
Therapeutic drug monitoring. A drug-drug interaction is never straightforward, because not all patients will be effected to the same degree when they experience a drug-drug interaction. Therapeutic drug monitoring is an important tool for identifying the extent of the interaction and may help resolve actual and potential problems. Therapeutic drug monitoring can be used to guide dosing and to optimize therapy to prevent subtherapeutic effects or toxicity [55] .
PRACTICAL ISSUES FOR USE OF THE DRUG-INTERACTION TABLE
Our drug-interaction table, which has a risk-ranking order of categories adapted from the UptoDate Lexi-Interact Tool [56] (table 1), provides an overview of drug-drug interactions published in peer-reviewed journals. The interactions that are most severe are listed first. This type of grading system helps the clinician to judge which drug combinations should be avoided and which drug combinations can be used safely. Futhermore, we have defined 9 areas of study that we consider to be necessary to review before making a judgement on the drug-drug interaction. In one area of study, various authors have provided recommendations on how to deal with the specific drug-drug interactions. Both the risk ranking and the recommendations reflect the opinions of the authors of the present article and are based on the interpretation of (multiple) studies and gathered information. Our recommendations may therefore differ slightly from the recommendations of the authors of the studies cited.
CONSIDERATIONS
We aimed to provide a comprehensive review of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents in the treatment of invasive fungal diseases. New information is emerging rapidly, and thus, this review is by its very nature incomplete. Awareness of the mechanisms involved in these interactions is pivotal for the optimization of treatment of patients requiring antifungal therapy. For the clinical interpretation, it should be kept in mind that much of the data presented in our review are from studies of healthy volunteers or a limited number of patients, and the clinical setting may therefore differ from the controlled setting of an interaction study. Drug-drug interactions do not only occur when therapy is initiated; they can also become evident after the drug therapy is stopped, particularly if the agent in question is an enzyme inducer, because this might lead to toxic concentrations.
Therapeutic drug monitoring is a valuable tool for assessing the effect of a drug-drug interaction for both the antifungal azole drug and, if possible, the coadministered drug. To perform therapeutic drug monitoring, a validated analytical method has to be available to determine whole blood or plasma concentrations. Assays have to be validated to ensure accuracy and precision. The measurement of samples can be done by inhouse laboratory technicians, if facilities are available, or sent to reference laboratories with validated assays. The shorter the turnaround time (for instance, within 48 h), the better (for prompt patient management). Interpretation of the results can be performed by a clinical pharmacist and/or pharmacologist or by another health care professional who is familiar with therapeutic drug monitoring. Finally, addressing the problem of drug-drug interactions is a multidisciplinary task, with the goal of minimizing unwanted adverse effects while optimizing patient care.
